Puma Biotechnology (NASDAQ:PBYI) Getting Somewhat Favorable Press Coverage, Accern Reports

News coverage about Puma Biotechnology (NASDAQ:PBYI) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Puma Biotechnology earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.4787412064584 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern’s analysis:

Several research firms recently weighed in on PBYI. JPMorgan Chase & Co. restated a “buy” rating and issued a $131.00 target price on shares of Puma Biotechnology in a report on Wednesday, October 4th. Credit Suisse Group set a $142.00 target price on Puma Biotechnology and gave the stock a “buy” rating in a report on Monday. Bank of America restated a “buy” rating and issued a $135.00 target price (up from $117.00) on shares of Puma Biotechnology in a report on Monday, October 9th. Barclays restated a “buy” rating and issued a $122.00 target price (up from $103.00) on shares of Puma Biotechnology in a report on Friday, November 10th. Finally, Royal Bank of Canada cut their price target on Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating for the company in a report on Friday, November 10th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. Puma Biotechnology currently has a consensus rating of “Buy” and an average target price of $130.67.

Puma Biotechnology (NASDAQ:PBYI) traded down $8.40 on Tuesday, hitting $90.85. The stock had a trading volume of 1,027,342 shares, compared to its average volume of 639,870. The company has a market capitalization of $3,410.00, a PE ratio of -11.09 and a beta of 0.72. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.50) by $0.43. The firm had revenue of $6.10 million for the quarter, compared to the consensus estimate of $3.78 million. During the same quarter in the prior year, the firm posted ($1.11) earnings per share. sell-side analysts forecast that Puma Biotechnology will post -8.17 EPS for the current year.

In other news, insider Charles R. Eyler sold 1,322 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $105.46, for a total transaction of $139,418.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 21.10% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Puma Biotechnology (NASDAQ:PBYI) Getting Somewhat Favorable Press Coverage, Accern Reports” was published by BBNS and is the property of of BBNS. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/puma-biotechnology-pbyi-receiving-somewhat-positive-media-coverage-analysis-shows/1821703.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Insider Buying and Selling by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.